Cerapedics was awarded a group purchasing agreement with Premier for Breakthrough Technology: Bone Tissue Synthetic Implantable Products.
The agreement, effective 12/1/16, allows Premier’s ~3,750 U.S. hospitals and 130,000 provider organizations to access special pricing and negotiated terms for i-FACTOR™ Peptide Enhanced Bone Graft.
Cerapedics developed i-FACTOR synthetic small peptide technology to support bone growth through cell attachment and activation. The 4Q15 PMA for i-FACTOR represented the first approval of bone graft for use in the cervical spine, and the second PMA-approved bone graft in the spine (the first being INFUSE).
Cerapedics was awarded a group purchasing agreement with Premier for Breakthrough Technology: Bone Tissue Synthetic Implantable Products.
The agreement, effective 12/1/16, allows Premier's ~3,750 U.S. hospitals and 130,000 provider organizations to access special pricing and negotiated terms for i-FACTOR™ Peptide Enhanced Bone Graft. ...
Cerapedics was awarded a group purchasing agreement with Premier for Breakthrough Technology: Bone Tissue Synthetic Implantable Products.
The agreement, effective 12/1/16, allows Premier’s ~3,750 U.S. hospitals and 130,000 provider organizations to access special pricing and negotiated terms for i-FACTOR™ Peptide Enhanced Bone Graft.
Cerapedics developed i-FACTOR synthetic small peptide technology to support bone growth through cell attachment and activation. The 4Q15 PMA for i-FACTOR represented the first approval of bone graft for use in the cervical spine, and the second PMA-approved bone graft in the spine (the first being INFUSE).
Copy to clipboard 
